“GLP-1” has become the most important three-letter phrase in modern medicine, and the entire Motley Fool “King Kong for Weight Loss” pitch is, at its core, a GLP-1 story. These are the drugs behind Ozempic, Wegovy, Mounjaro, and Zepbound, and they have turned a niche metabolic treatment into one of the largest commercial opportunities the pharmaceutical industry has ever seen. Here is what GLP-1 stocks actually are, how the category breaks down, and what investors should understand before buying into the theme.

What GLP-1 Actually Means

GLP-1 stands for glucagon-like peptide-1, a hormone the body releases after eating. It does several useful things at once: it signals fullness, slows stomach emptying, and prompts the pancreas to release insulin. The first GLP-1 drugs were developed for type 2 diabetes, but researchers quickly noticed the side effect that changed everything: patients lost weight, a lot of it, in a sustained way.

The newer generation goes further by adding more receptors. Some drugs now target two hormones at once, GLP-1 plus GIP, and the most advanced experimental medicine, retatrutide, targets three, adding glucagon on top. Each additional receptor is meant to widen the gap between what patients experience and what older drugs could do. That progression is why the category keeps expanding rather than plateauing.

Why the Market Is So Large

The addressable market is the source of all the enthusiasm. Obesity affects hundreds of millions of people globally, and until recently the treatment options were limited and mostly ineffective. A class of drugs that reliably produces double-digit percentage weight loss opened up a commercial opportunity that looks, by some estimates, like one of the biggest drug markets in history.

The demand side is already visible. Shortages have been a recurring theme for the leading products, and the companies that make them have scrambled to build manufacturing capacity fast enough to keep up. That is not a typical problem for a pharma launch, and it signals how deep the underlying demand runs.

The Two Giants and the Challengers

The category is currently led by two companies that hold most of the market between them. Novo Nordisk makes semaglutide, sold as Ozempic for diabetes and Wegovy for obesity. Eli Lilly makes tirzepatide, sold as Mounjaro and Zepbound, and is developing retatrutide, the triple receptor agonist at the center of the Fool’s pitch.

Around those two giants sit a growing cast of challengers. Ascendis Pharma is working on a once-monthly version of semaglutide. Viking Therapeutics is developing an oral and injectable candidate called VK2735. Hims & Hers Health plays a different role entirely, selling compounded semaglutide through a telehealth platform. And a number of smaller companies, including Veru, are pursuing early-stage oral candidates. The key point is that this is a competitive field, not a single-winner market, even if the two leaders look entrenched today.

Injectables Versus Pills

The next chapter of the GLP-1 story is a format shift. Today’s blockbusters are injections, taken weekly. A once-daily oral pill would remove the needle entirely, and that matters for the large share of patients who will not inject under any circumstances. Several oral candidates are in development, including Novo Nordisk’s oral semaglutide and Eli Lilly’s orforglipron.

This is where the Fool’s “the playing field is about to be redrawn” language comes from, and there is truth in it. But it is worth being specific: the redrawing benefits the category as a whole more than it guarantees any single winner. A pill expands the market; it does not hand one company a monopoly over it.

How to Think About GLP-1 Stocks

The first rule is to separate quality from price. Some of these companies are trillion-dollar diversified pharma giants, some are revenue-growing biotechs, and some are pre-revenue clinical-stage bets with a binary risk profile. Bundling them under one “GLP-1 stocks” label hides how different the downside is across those buckets.

The second rule is to respect the timeline. Drug development, even for a hot category, takes years, and trial readouts can move a pre-revenue stock sharply in either direction. For the full picture of how the Fool’s promo frames the deadline and the six picks, see our King Kong weight loss teardown. For a look at the companies themselves rather than the stocks, our obesity drug companies explainer is the natural next read.

The Risks

The category carries three main risks. The first is tolerability, because the most powerful drugs also produce the most gastrointestinal side effects, and real-world adherence can fall short of what trials show. The second is competition and pricing, as insurers push back on the cost of drugs taken indefinitely by huge populations. The third is regulatory, particularly around compounded versions, whose legal footing depends on ongoing shortages. None of these is a reason to dismiss the theme, but each is a reason to be selective about how you buy it.

Ready to see the research? Click here to access The Motley Fool’s report.

NewsletterVetter is an independent publication. We receive compensation from some of the services we review through affiliate links. Nothing on this site is investment advice. Always do your own research.